Leerink Swann Upgrades Illumina; Revises Estimates for Life Tech, Thermo Fisher, Others | GenomeWeb

NEW YORK (GenomeWeb News) – Leerink Swann today upgraded Illumina to an Outperform rating, saying the demand for its HiSeq next-generation sequencing platform has normalized, while interest among researchers in sequencing has remained high.

Separately, the investment firm revised estimates for Life Technologies, Thermo Fisher Scientific, Affymetrix, PerkinElmer, Bio-Rad Laboratories, Bruker, and Waters.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.